Muse Related Published Studies
Well-designed clinical trials related to Muse (Alprostadil)
Alprostadil infusion in patients with dry age related macular degeneration: a
randomized controlled clinical trial. [2013]
[Clinical effects of alprostadil injection on acute kidney injury after cardiac surgical procedures]. [2010.08.24]
Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. [2010.06]
Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. [2009.02]
[Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases] [2008.11.11]
Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. [2007.10]
Effects of pentoxifylline and alprostadil on ocular hemodynamics in healthy humans. [2007.02]
[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)] [2007]
An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. [2006.08]
Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy. [2006.03]
[Reevaluation of protective effects of alprostadil on hepatic function in patients undergoing hepatectomy] [2005.09]
Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. [2005.01]
Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1). [2004.08]
Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study. [2004.02]
Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. [2004]
Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. [2003.10]
Intravenous alprostadil, an analog of prostaglandin E1, prevents thiamylal-fentanyl-induced bronchoconstriction in humans. [2003.08]
The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. [2003.02]
Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction. [2002.12]
Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. [2002.12]
A synthetic prostaglandin E1 analog, alprostadil alfadex, relaxes sphincter of Oddi in humans. [2002.01]
A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. [2001.02]
Effect of intravenous iloprost and alprostadil (PGE1) on peripheral resistance during femoro-distal reconstructions. [2000.12]
Optimizing the therapeutic approach of transurethral alprostadil. [2000.07]
Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. [2000.01]
Intracavernosal versus intraurethral alprostadil: a prospective randomized study. [1999.05]
The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. [1998.12]
Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. [1998.06]
Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. [1998.05]
Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. [1998.01]
Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators. [1997.11]
Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators. [1997.11]
Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. [1997.10]
Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. [1997.01.02]
A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. [1996.12]
A cost analysis of alprostadil in liver transplantation. [1996.06]
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. [1996.04.04]
Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. [1996.04]
Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction. [1996]
A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group. [1995.11]
Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. [1995.09]
An alprostadil analogue and human gastric secretion. A double-blind placebo-controlled study of the effects of a capsule and tablet formulation. [1989.07]
An alprostadil analogue and human gastric secretion. A double-blind placebo-controlled study of the effects of a tablet and lyovial formulation. [1987.08]
Well-designed clinical trials possibly related to Muse (Alprostadil)
Effect of nitazoxanide in adults and adolescents with acute uncomplicated
influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. [2014]
The significance of natriuretic peptide in treatment of pulmonary hypertension
after mitral valve replacement. [2014]
A dose-finding study of sufentanil sublingual microtablets for the management of
postoperative bunionectomy pain. [2014]
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of
4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy
adult volunteers. [2013]
Mindfulness-based cognitive therapy for severe health anxiety (hypochondriasis): an interpretative phenomenological analysis of patients' experiences. [2011.11]
A trial of an impedance threshold device in out-of-hospital cardiac arrest. [2011.09.01]
Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest. [2011.09.01]
Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy: a prospective randomized study. [2011.07]
Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. [2011.06]
Changes in penile length after robot-assisted laparoscopic radical prostatectomy. [2011.01]
[Multicenter randomized, double-blind, placebo-controlled trial of prostaglandin E1 cream for female sexual arousal disorder]. [2010.12.18]
Safety of anacetrapib in patients with or at high risk for coronary heart disease. [2010.12.16]
Feasability of a novel audio-video sexual stimulation system: an adjunct to the use of penile duplex Doppler ultrasonography for the investigation of erectile dysfunction. [2010.12]
Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. [2010.11]
Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. [2010.10]
Effects of intravenous prostaglandin E1 on pain and body temperature in patients with post-herpetic neuralgia. [2010.04]
Efficacy and safety of lubiprostone in patients with chronic constipation. [2010.04]
[Therapeutic effect of prostaglandin E1 on diabetic nephropathy: a one-year follow-up study]. [2010.03]
Estimating a meaningful reduction in menstrual blood loss for women with heavy
menstrual bleeding. [2010]
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled
trial. [2010]
Prostaglandin E1 for preventing the progression of diabetic kidney disease. [2010]
Topical treatment of erectile dysfunction with prostaglandin E ethyl ester. [2009.12]
The effects of prostaglandin E1 on interleukin-6, pulmonary function and postoperative recovery in oesophagectomised patients. [2009.11]
Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. [2009.11]
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. [2009.10]
Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. [2009.08]
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. [2009.02.01]
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. [2009.02]
The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. [2009.01.15]
Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. [2009.01]
Improvement of microcirculation after percutaneous transluminal angioplasty in the lower limb with prostaglandin E1. [2009.01]
Vaginal versus oral misoprostol for second-trimester pregnancy termination: a randomized trial. [2008.11.01]
Single-dose lubiprostone along with split-dose PEG solution without dietary restrictions for bowel cleansing prior to colonoscopy: a randomized, double-blind, placebo-controlled trial. [2008.09]
Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction. [2008.09]
Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1. [2008.07]
Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. [2008.06]
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. [2008.04]
Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). [2008.01]
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. [2008.01]
Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. [2007.10]
Efficacy and safety of misoprostol in induction of labour in a Nigerian tertiary hospital. [2007.07]
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. [2007.06.01]
Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. [2007.05]
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. [2007.02]
Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. [2006.12]
Intraamniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy. [2006.06.01]
The effects of prostaglandin E-1 in patients with intermittent claudication. [2006.06]
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. [2006.05]
Prostaglandin E1 attenuates impairment of cellular immunity after cardiopulmonary bypass. [2006.04]
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. [2006.04]
Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. [2006.03.01]
Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. [2006.03]
An investigation of misoprostol in the promotion of wound healing. [2006]
Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. [2005.12]
Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. [2005.12]
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. [2005.12]
Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs. [2005.08]
|
